Background And Aims: The study aimed to assess the potential of proteoglycans (PGs) and collagens as serological biomarkers in the abdominal aortic aneurysm (AAA). Furthermore, we investigated the underlying mechano-biological interactions and signaling pathways.
Methods: Tissue and serum samples from patients with ruptured AAA (rAAA; = 29), elective AAA (eAAA; = 78), and healthy individuals ( = 8) were evaluated by histology, immunohistochemistry, and enzyme-linked immunosorbent assay, and mechanical properties were assessed by tensile tests. Regulatory pathways were determined by membrane-based sandwich immunoassay.
Results: In AAA samples, collagen type I and III (Col1 and Col3), chondroitin sulfate, and dermatan sulfate (DS) were significantly increased compared with controls (3.0-, 3.2-, 1.3-, and 53-fold; < 0.01). Col1 and endocan were also elevated in the serum of AAA patients (3.6- and 6.0-fold; < 0.01), while DS was significantly decreased (2.5-fold; < 0.01). Histological scoring showed increased total PGs and focal accumulation in rAAA compared with eAAA. Tissue β-stiffness was higher in rAAA compared with eAAA (2.0-fold, = 0.02). Serum Col1 correlated with maximum tensile force and failure tension ( = 0.448 and 0.333; < 0.01, and = 0.02), tissue endocan correlated with α-stiffness ( = 0.340; < 0.01). Signaling pathways in AAA were associated with extracellular matrix synthesis and vascular smooth muscle cell proliferation. In particular, Src family kinases and platelet-derived growth factor- and epidermal growth factor-related proteins seem to be involved.
Conclusion: Our findings reveal a structural association between collagen and PGs and their response to changes in mechanical loads in AAA. Particularly Col1 and endocan reflect the mechano-biological conditions of the aortic wall also in the patient's serum and might serve for AAA risk stratification.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1055/a-1772-0574 | DOI Listing |
Ocul Surf
November 2024
Department of Ophthalmology, NYU Grossman School of Medicine, Science Building, Fifth Floor 435 E 30th, New York, NY, USA; Department of Pathology, NYU Grossman School of Medicine, New York, NY, USA. Electronic address:
Purpose: We developed human cornea organoids (HCOs) from induced pluripotent stem cells (iPSCs) where single-cell RNA-sequence (scRNA-seq) analysis suggested similarity with developing rather than mature human corneas. We performed immunohistology to determine the presence of corneal glycosaminoglycans as an assessment of maturity. We undertook a detailed comparison of the HCO scRNA-seq data with a recent scRNA-seq study of human fetal corneas at different stages to gauge the HCO's maturity.
View Article and Find Full Text PDFJ Colloid Interface Sci
February 2025
Laboratory of Pharmaceutical Nanomaterials Science, Department of Materials Science and Engineering Technion - Israel Institute of Technology, Technion City 320003, Haifa, Israel. Electronic address:
RNA interference, a naturally occurring regulatory mechanism in which small interfering RNA (siRNA) molecules are responsible for the sequence-specific suppression of gene expression, emerged as one of the most promising gene therapies in cancer. In this work, we investigate a microfluidics double self-assembly method based on micellization and polyelectrolyte complex formation for the encapsulation of siRNA targeting the BIRC5 gene, a member of the inhibitor of apoptosis gene family, that codes for survivin a protein of theinhibitorof apoptosis protein family that is involved in triple-negative breast cancer (TNBC) proliferation and metastasis within nanoparticles of an amphiphilic chitosan-graft-poly(methyl methacrylate) copolymer and low-molecular weight dermatan sulfate, a polysaccharide targeting the CD44 receptor overexpressed in this tumor. Nanoparticles are spherical and display a hydrodynamic diameter of ∼ 200 nm, as measured by dynamic light scattering and scanning electron microscopy.
View Article and Find Full Text PDFAnal Chem
November 2024
The Rosalind Franklin Institute, Harwell Campus, Didcot OX11 0FA, U.K.
Case Rep Ophthalmol
August 2024
Reference Center of Inherited Metabolic Diseases, Centro Hospitalar Universitário de São João, Porto, Portugal.
Introduction: Mucopolysaccharidosis type VI (MPS VI) is a rare inherited metabolic disorder, primarily attributed to the deficiency of the enzyme N-acetylgalactosamine-4-sulfatase, responsible for the degradation of dermatan sulfate and chondroitin-4-sulfate. Therefore, there is a widespread accumulation of partially degraded glycosaminoglycans. Corneal opacification is the hallmark ocular feature in the MPS.
View Article and Find Full Text PDFJ Inherit Metab Dis
January 2025
Department of Pediatric Cardiology and Structural Heart Diseases, Center for Diseases in Childhood and Adolescence, University Medicine Mainz, Mainz, Germany.
Mucopolysaccharidosis II (MPS II, Hunter syndrome) is a rare, X-linked lysosomal storage disease caused by reduced activity of iduronate-2-sulfatase (I2S), with subsequent cellular accumulation of the glycosaminoglycans (GAGs), heparan sulfate, and dermatan sulfate (DS). DS is a major component of the extracellular matrix of heart valves, which can be affected in MPS II. We investigated the natural history of valve disease in MPS II and the impact of long-term intravenous enzyme replacement therapy (ERT) with recombinant I2S (idursulfase).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!